Abbott Laboratories

3. Abbott Laboratories (before the spinoff into AbbVie)

Total Ad Spend: $301.7 million
Television: $264 million
Magazine: $35 million
Other: $2.7 million

Blockbuster Humira was the driving force behind Abbott Laboratories ($9.2 billion in sales in 2012) and now holds that distinction for AbbVie ($ABBV), the brand-new spinoff that took all of Abbott's ($ABT) pharma assets. Even the current top-selling drug worldwide can benefit from some advertising.

In the spotlight


Humira for arthritis, $84.5 million
AndroGel, $80 million
Humira for Crohn's disease, $57.2 million


 

Abbott Laboratories
Read more on

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.